VRTX – Vertex Pharmaceuticals Stock: Vertex Pharmaceuticals continues to innovate in the healthcare sector, so investors are keeping an eye on its stock performance. Our comprehensive analysis spans from 2025 to 2030, providing valuable insights for investors and healthcare enthusiasts.
Whether you’re aiming to make informed investment decisions or are simply interested in market trends, this forecast is based on expert predictions, key market indicators, and more.
Join us as we explore the potential trajectory of Vertex Pharmaceuticals’ stock, helping you navigate the dynamic world of healthcare investing.
Vertex Pharmaceuticals (VRTX) Company Overview
- Company Name: United Parcel Service Inc.
- Founded: 1989
- Headquarters: Boston, Massachusetts, U.S.
- Industry: Pharmaceuticals, Biotherapeutics
- Chairman: Jeffrey Leiden
- Stock Exchange Listing: NASDAQ, S&P
- Official Website: vrtx.com
Vertex Pharmaceuticals (VRTX) Fundamental Analysis
- Market Cap: $113,704 M
- ROE: -0.03%
- ROCE: 22.03%
- P/E Ratio: —
- P/B Ratio: 7.27
- Industry P/E: —
- Debt to Equity: 0
- Div. Yield: 0%
- Book Value: —
- EPS (TTM): -2
- 52 Weeks High: $519.88
- 52 Weeks Low: $378.00
Also Read: United Parcel Service – UPS Stock Forecast
Vertex Pharmaceuticals (VRTX) Financials
Income Statement
| USD | 2023 | Y/Y Change |
|---|---|---|
| Revenue | 9.87B | 10.51% |
| Operating Expense | 1.14B | 20.31% |
| Net Income | 3.62B | 8.96% |
| Net Profit Margin | 36.68 | -1.40% |
| Earnings Per Share | 15.23 | 2.35% |
| EBITDA | 4.48B | -1.10% |
| Effective Tax Rate | 17.36% | — |
Balance Sheet
| USD | 2023 | Y/Y Change |
|---|---|---|
| Cash and Short-term Investments | 11.22B | 4.08% |
| Total Assets | 22.73B | 25.23% |
| Total Liabilities | 5.15B | 21.51% |
| Total Equity | 17.58B | — |
| Shares Outstanding | 258.31M | — |
| Price to Book | 6.43 | — |
| Return on Assets | 13.17% | — |
| Return on Capital | 16.22% | — |
Cash Flow
| USD | 2023 | Y/Y Change |
|---|---|---|
| Net Income | 3.62B | 8.96% |
| Cash from Operations | 3.54B | -14.35% |
| Cash from Investing | -3.14B | -878.42% |
| Cash from Financing | -562.20M | -730.43% |
| Net Change in Cash | -139.70M | -103.76% |
| Free Cash Flow | 3.51B | 6.13% |
Also Read: Walgreens Boots Alliance – WBA Stock Forecast
VRTX – Vertex Pharmaceuticals Stock Price Prediction 2025 to 2030
| Years | Target Price |
|---|---|
| Vertex Pharmaceuticals Stock Forecast 2025 | $599 |
| Vertex Pharmaceuticals Stock Forecast 2026 | $683 |
| Vertex Pharmaceuticals Stock Forecast 2027 | $790 |
| Vertex Pharmaceuticals Stock Forecast 2028 | $868 |
| Vertex Pharmaceuticals Stock Forecast 2029 | $983 |
| Vertex Pharmaceuticals Stock Forecast 2030 | $1112 |
Vertex Pharmaceuticals Major Holdings
- % of Shares Held by All Insiders – 0.08%
- % of Shares Held by Institutions – 95.82%
- % of Float Held by Institutions – 95.90%
- Number of Institutions Holding Shares – 2,159
Also Read: Exxon Mobil Corp – XOM Stock Forecast
Vertex Pharmaceuticals Top Shareholders
- Capital World Investors: 10.41%
- Vanguard Group Inc: 8.99%
- Blackrock Inc: 8.46%
- State Street Corporation: 4.59%
- FMR, LLC: 4.09%
- Capital Research Global Investors: 3.50%
- Alliancebernstein L.P.: 2.86%
- JP Morgan Chase & Company: 2.69%
- Geode Capital Management, LLC: 2.30%
- Wellington Management Group, LLP: 1.86%
Vertex Pharmaceuticals (VRTX) Top Mutual Fund Holders
- Vanguard Total Stock Market Index Fund: 3.18%
- Growth Fund of America Inc: 3.15%
- Vanguard 500 Index Fund: 2.62%
- Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF: 1.99%
- American Balanced Fund: 1.93%
- New Perspective Fund Inc: 1.43%
- Fidelity Contrafund Inc: 1.33%
- Fidelity 500 Index Fund: 1.24%
- SPDR S&P 500 ETF Trust: 1.24%
- Capital World Growth and Income Fund: 1.18%
VRTX Competitors/Peer Companies
- Amgen (AMGN)
- Gilead Sciences (GILD)
- Regeneron Pharmaceuticals (REGN)
- Alnylam Pharmaceuticals (ALNY)
- Biogen (BIIB)
- United Therapeutics (UTHR)
- Neurocrine Biosciences (NBIX)
- Incyte (INCY)
- BioMarin Pharmaceutical (BMRN)
- Exact Sciences (EXAS)
Also Read: TSM Stock Price Prediction
To connect with us, click on any of the given social media buttons.
Disclaimer: The information in this blog is for educational purposes only, and the targets mentioned in it are given as suggestions by market analysts. Therefore, before investing your money in any company, it is mandatory to get complete information about the company and consult your financial advisor.
With 5.5 years of experience in financial journalism, I am a content writer who specializes in international markets. My aim is always to deliver unbiased and factual reporting.